Behavioural Intervention
Carbohydrate Loading for Type 2 Diabetes in Colorectal Surgery
This trial will help determine if it is safe for patients with type 2 diabetes to drink a sugar-based drink before surgery, in order to potentially decrease complications.
Behavioral Intervention
Family vs Standard Diabetes Education for Type 2 Diabetes
This trial will compare the effectiveness of a diabetes education program that includes family members to a diabetes education program that does not include family members.
Behavioral Intervention
Food & Video-Based Nutrition Education for Type 2 Diabetes
This trial will compare how well two different methods - medically tailored meals and medical nutrition therapy via telehealth - help patients with poorly controlled type 2 diabetes. The goal is to see if these interventions can improve outcomes by impacting self-care behaviors and diet self-efficacy.
Behavioral Intervention
Texting Intervention for Diabetes
This trial will help to develop a new customizable, interactive texting intervention called DD-TXT that allows Veterans to choose what kinds of diabetes self-management support they need, and when. This diabetes support will be provided to Veterans through "Annie", a new VA texting system for self-management support.
Popular Filters
Trials for Type 2 Diabetes Patients
Continuous Glucose Monitoring for Diabetes
This trial is testing a new system called the Glucose Telemetry System (GTS) that sends blood sugar levels from a patient's bedside to a monitor at the nurse's station. It aims to help hospitalized Veterans with diabetes by preventing dangerously low blood sugar levels. The system allows nurses to keep track of patients' blood sugar without entering the room often. A new system has been developed to monitor blood sugar levels in diabetic patients.
Behavioural Intervention
Medication Optimization Intervention for HIV/AIDS
This trial will compare the health outcomes of two groups of African-Americans with HIV who either receive medication optimization with access to their medical records or usual care without access to records.
Trials for T2D Patients
Continuous Glucose Monitoring for Diabetes
This trial is testing a new system called the Glucose Telemetry System (GTS) that sends blood sugar levels from a patient's bedside to a monitor at the nurse's station. It aims to help hospitalized Veterans with diabetes by preventing dangerously low blood sugar levels. The system allows nurses to keep track of patients' blood sugar without entering the room often. A new system has been developed to monitor blood sugar levels in diabetic patients.
Behavioural Intervention
Medication Optimization Intervention for HIV/AIDS
This trial will compare the health outcomes of two groups of African-Americans with HIV who either receive medication optimization with access to their medical records or usual care without access to records.
Phase 3 Trials
GLP-1 Receptor Agonist
Oral Semaglutide for Type 2 Diabetes in Youth
This trial is testing a new diabetes medicine called semaglutide. It focuses on children and teenagers with type 2 diabetes to see if the new medicine is safe and effective. Semaglutide helps control blood sugar levels, which is crucial for managing diabetes. It has been shown to improve blood sugar control and promote weight loss in patients with type 2 diabetes.
Insulin
Inhaled Insulin for Diabetes in Children
This trial tests an inhalable insulin called Afrezza, combined with a long-acting insulin, in children and teenagers with diabetes. Afrezza helps lower blood sugar quickly after eating, and the long-acting insulin keeps it stable all day. The study aims to see if this combination is safe and effective.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Tirzepatide for Pediatric Type 2 Diabetes
This trial is testing tirzepatide, a medication that helps control blood sugar levels, in children and teenagers with type 2 diabetes. These participants are already taking other diabetes medications like metformin or basal insulin. Tirzepatide works by helping the body use insulin more effectively and reducing sugar production in the liver. Tirzepatide is a new medication being tested for its effectiveness and safety in people with type 2 diabetes.
GLP-1 Receptor Agonist
Semaglutide + Low-Dose Insulin Glargine for Type 2 Diabetes
This trial compares semaglutide with insulin glargine in people with type 2 diabetes, looking at how well they control blood sugar levels. Participants will take one medicine or the other for 47 weeks and have 9 clinic visits, 15 phone/video calls, and 1 home visit. They will also wear a sensor measuring blood sugar for 2 periods of 10 days.
Trials With No Placebo
Behavioural Intervention
Medication Optimization Intervention for HIV/AIDS
This trial will compare the health outcomes of two groups of African-Americans with HIV who either receive medication optimization with access to their medical records or usual care without access to records.
View More Related Trials
Frequently Asked Questions
Introduction to diabetes type 2
What are the top hospitals conducting diabetes type 2 research?
When it comes to advancing treatment options for individuals living with type 2 diabetes, several leading hospitals are making significant contributions through their clinical trials. In Los Angeles, the University of Southern California takes a proactive approach with three ongoing trials dedicated to type 2 diabetes, building upon their track record of six completed studies since initiating research in this area back in 2013. Meanwhile, on the opposite coast in Boston, the Joslin Diabetes Center is also at the forefront of innovative therapies. With two active trials and an impressive history of 33 previous studies focusing on type 2 diabetes since their first trial in 2001, they continue to push boundaries for improved management and care.
Additionally joining this effort are Novo Nordisk Investigational Sites located in La Mesa and Los Angeles respectively. These sites have been actively involved in conducting essential research by running two current clinical trials each related specifically to type 2 diabetes while having accomplished twelve past investigations starting as early as2003 and fifty-seven extensive explorations beginning from year2002 consecutively.In another location within San Diego lies yet another Novo Nordisk Investigational Site conducting similar pioneering endeavors; they currently maintain two ongoing tests concerning type- II-diabetes.With thirty-five prior projects undertaken relating especially towards managing this condition which initiated from year2006 itself.
These esteemed institutions demonstrate not only commitment but also collaboration towards finding more effective treatments for those affected by type 2 diabetes. By participating in these clinical trials, patients help pave the way for future breakthroughs that hold promise for millions living with this chronic disease worldwide
Which are the best cities for diabetes type 2 clinical trials?
When it comes to diabetes type 2 clinical trials, several cities across the United States are at the forefront of research and innovation. San Antonio, Texas emerges as a top destination with its eight ongoing trials investigating treatments like Empagliflozin, Mifepristone 300 mg, Semaglutide, and lifestyle interventions. Los Angeles, California follows closely behind with seven active studies focusing on therapies such as Mifepristone 300 mg and Peer Support Groups. Atlanta, Georgia; Austin, Texas; and Boston Massachusetts also contribute significantly to diabetes type 2 research through their respective clinical trials exploring various treatment options for improved management and understanding of this chronic condition.
Which are the top treatments for diabetes type 2 being explored in clinical trials?
Clinical trials are actively exploring potential treatments for type 2 diabetes, with two notable contenders in the spotlight. Semaglutide has emerged as a leading candidate, currently undergoing four active trials and accumulating a total of 58 trials dedicated to diabetes type 2 since its debut in 2017. Another innovative approach is the Community Health Navigator Program, which aims to provide support and guidance through three ongoing clinical trials. Introduced recently in 2021, this program shows promise as an alternative avenue for managing and treating type 2 diabetes. As research progresses, these developments offer hope for improving the lives of individuals living with this chronic condition.
What are the most recent clinical trials for diabetes type 2?
Recent clinical trials offer promising insights into the management of type 2 diabetes. The MANAGe-DM trial, currently in Phase 3, presents a potential breakthrough in the field. Another noteworthy study is Active, which has shown positive results in Phase 1 and Phase 4 for individuals with diabetes type 2. Additionally, there are two ongoing trials involving semaglutide and mifepristone that aim to evaluate their efficacy when combined with lifestyle interventions or used as standalone treatments for type 2 diabetes patients. These studies represent significant advancements toward improving treatment options and outcomes for individuals living with this condition.
What diabetes type 2 clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of diabetes type 2. In August 2022, Pfizer successfully completed a trial for PF-07081532, while Glyscend, Inc.'s trial investigating GLY-200 also concluded during the same month. Vanderbilt University Medical Center's study on L-Lysine came to an end in March 2022, along with Gan and Lee Pharmaceuticals' trial testing GZR-18. Other notable trials include Altimmune, Inc.'s completion of their study on ALT-801 in February 2022 and Sanofi's trial evaluating Insulin glargine/Lixisenatide in January 2022. These pioneering efforts by various organizations highlight the ongoing commitment to advancing treatments for patients living with diabetes type 2.